{"id":7562,"date":"2023-10-25T16:01:34","date_gmt":"2023-10-25T14:01:34","guid":{"rendered":"https:\/\/www.shs-capital.eu\/?p=7562"},"modified":"2025-09-02T07:25:05","modified_gmt":"2025-09-02T06:25:05","slug":"pathoquest-publishes-study-on-proprietary-ngs-based-quality-control-test","status":"publish","type":"post","link":"https:\/\/www.shs-capital.eu\/pathoquest-publishes-study-on-proprietary-ngs-based-quality-control-test\/","title":{"rendered":"PathoQuest publishes study on proprietary NGS-based quality control test"},"content":{"rendered":"<p>Paris-based SHS portfolio company PathoQuest SAS is a leader in the development and delivery of next-generation sequencing (NGS) tests for biopharmaceuticals. PathoQuest recently published a study with Charles River Laboratories International Inc. showing that PathoQuest&#8217;s GMP-compliant, NGS-based test demonstrates greater ability to detect viral contamination compared to in vivo tests.<\/p>\n<p>The aim of the study was to compare conventional in vivo assays used to screen cell lines for adventitious viruses with a GMP-compliant viral transcriptome NGS assay. The study was conducted as a direct comparison of standard in vivo assays and NGS-based assays of cell substrates. Charles River&#8217;s leading experts prepared the test materials and performed the in vivo tests, while PathoQuest&#8217;s team tested the material using its proprietary NGS-based quality control.<\/p>\n<p>More information: <a href=\"https:\/\/pathoquest.com\/ngs-vs-in-vivo-2\/\" target=\"_blank\" rel=\"noopener noreferrer\">link<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris-based SHS portfolio company PathoQuest SAS is a leader in the development and delivery of next-generation sequencing (NGS) tests for biopharmaceuticals. PathoQuest recently published a study with Charles River Laboratories International Inc. showing that PathoQuest&#8217;s GMP-compliant, NGS-based test demonstrates greater ability to detect viral contamination compared to in vivo tests. The aim of the study [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5799,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[90],"tags":[],"class_list":["post-7562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-shs-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/posts\/7562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/comments?post=7562"}],"version-history":[{"count":0,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/posts\/7562\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/media\/5799"}],"wp:attachment":[{"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/media?parent=7562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/categories?post=7562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/tags?post=7562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}